First-quarter profit beat expectations, order growth accelerated, target price raised to ¥9,900

Overview

The report reviews Harmonic Drive Systems' FY3/27 first-quarter results for the period ending June 2026. Sales were in line with expectations, but operating profit and net profit exceeded market consensus by 34% and 20%, respectively, demonstrating operating leverage from revenue growth, an improved product mix, and higher capacity utilization. The company also raised its full-year targets, prompting Deutsche Bank to increase its earnings forecasts and valuation while maintaining its Buy rating.

Core views

In the short term, rapid order growth in semiconductor equipment and medical equipment, with the order-to-sales ratio rising to about 1.45x, provides support for subsequent revenue; margin improvement is also faster than expected. In the medium term, global semiconductor capital expenditure expansion, aerospace business growth, and strong demand in the United States and Japan are expected to sustain the recovery. In the long term, the company has advantages in harmonic reducer technology, global capacity layout, and its non-China supply chain attributes, and plans to expand the value of its humanoid robot business through actuator products whose content value is about three times that of reducers.

Analysis framework

The report forms its judgment by combining quarterly profit and loss comparisons with market consensus, orders broken down by end market and region, capacity utilization and margin trends, earnings forecast revisions, and scenario analysis; valuation uses a sum-of-the-parts approach, pricing the mature base business, aerospace business, and humanoid robot business separately.

Methodology notes

• Valuation methodsSum-of-the-Parts Valuation (SOTP)

  Values businesses with different growth stages, risk characteristics, and applicable valuation multiples separately and then aggregates them.

  The base business is valued at about 90x one-year forward P/E, the aerospace business at 6.5x FY3/27E P/S, and the humanoid robot business based on assumptions for 2030 market size and shares of reducers and rotary actuators, discounted back to 2027.

• Scenario AnalysisHumanoid Robot Business Scenario Valuation

  Measures the value range of a new business under different market share and product penetration assumptions.

  The base case assumes the global humanoid robot market reaches 1mn units in 2030, with HDS taking a 15% market share in reducers and a 3% market share in rotary actuators; the report also provides bull and bear valuation scenarios.

• Earnings ForecastOrder and Operating Leverage Analysis

  Uses order growth, order-to-sales ratio, revenue growth, and margin changes to assess earnings recovery.

  First-quarter orders increased 56% year on year, and operating margin rose to 11%, indicating that improving demand and rising capacity utilization are amplifying profit growth and supporting upward revisions to net profit forecasts for the next three years.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Harmonic Drive Systems (6324.T)

  Core covered company in the report and a beneficiary of harmonic reducers for humanoid robots, industrial automation, and precision motion control

  Strengths

  Leading reducer manufacturing technology; diversified production footprint in Japan, the United States, and Germany; strong demand from semiconductors, medical, and aerospace; higher capacity utilization driving margin recovery; potential to extend from reducers to higher-value actuators.

  Weaknesses

  China orders have declined continuously and may continue to lose share; valuation multiples are high; humanoid robot business still accounts for a limited share of current revenue; the company has historically failed to meet some medium-term targets.

  Comparison

  The report views HDS as an important global supplier of harmonic reducers for robots and a natural non-China alternative; its 2025 reducer revenue is about five times that of Leaderdrive, but Chinese domestic suppliers create pressure in terms of cost and local market competition.

  Risks

  Slow recovery in the traditional industrial robot market, humanoid robot commercialization falling short of expectations, reducer competition or technological substitution, price competition suppressing margins, and continued market share decline in China.

Key data

• First-quarter sales¥16.7bn, up 24% year on yearSales were broadly in line with market consensus.
• First-quarter operating profit¥1.8bn, up 1402% year on year34% above market consensus, with an operating margin of 11%.
• First-quarter net profit¥1.3bnNet loss was ¥38mn in the same period last year; this period was 20% above market consensus.
• Consolidated ordersUp 56% year on yearSignificantly faster than FY25's 16% growth rate, with an order-to-sales ratio of about 1.45x.
• Key end-market ordersMedical equipment up 179%, semiconductor equipment up 111%Medical equipment growth may include a one-off large order.
• Regional ordersNorth America up 126%, Japan up 52%, Europe up 37%, China down 23%China orders declined for four consecutive quarters, and first-quarter China revenue accounted for about 6% of group revenue.
• Raised full-year targetsSales ¥74.5bn, operating profit ¥8.5bn, net profit ¥6.0bnCorresponding to year-on-year growth of 25%, 40%, and 273%, respectively.
• Humanoid robot ordersAbout ¥1.25bn, up about 24% year on yearThe company is engaging with multiple humanoid robot customers in the United States and Japan.
• Humanoid robot revenue forecastFY3/27E ¥4.2bn, FY3/28E ¥9.0bnExpected to account for about 6% and 10% of group revenue, respectively.
• Earnings forecast revisionsFY3/27, FY3/28, and FY3/29 net profit forecasts raised by 33%, 31%, and 29%, respectivelyMainly reflecting stronger orders, higher capacity utilization, and margin improvement.
• Target price componentsBase business ¥4,866, aerospace ¥542, humanoid robots ¥4,492The three components together form the 12-month target price of ¥9,900.

Impact & implications

The earnings beat and full-year guidance upgrade enhance visibility on earnings forecasts. Strong orders imply that revenue recovery may continue, while higher capacity utilization can further drive margin recovery. The humanoid robot business accounts for about 45% of the target price, giving the stock dual drivers from an industrial automation recovery and a long-term emerging business, but also increasing valuation sensitivity to assumptions about 2030 market size, customer adoption, and market share.

Risks

• The global traditional industrial robot market recovers more slowly than expected.
• Humanoid robot market development and customer mass-production progress fall short of expectations.
• Competition among harmonic reducer manufacturers intensifies, or harmonic reducers are partially replaced by other transmission technologies.
• Intense price competition may weaken the extent of margin recovery.
• China orders have declined for four consecutive quarters, and regional market share may continue to be lost.
• High growth in medical equipment orders may include a one-off large order, and sustainability remains to be verified.
• The humanoid robot business accounts for a high proportion of the target price, so changes in long-term market size and share assumptions would significantly affect valuation.
• High valuation and the company's past record of missing some medium-term targets increase execution risk.

What to watch

• Whether consolidated order growth can translate into revenue, and whether the order-to-sales ratio can remain at a high level.
• Whether semiconductor equipment orders and global wafer fab equipment capital expenditure can continue to exceed expectations.
• Whether medical equipment order growth remains sustainable after excluding one-off large orders.
• Whether China orders, revenue contribution, and market share stabilize.
• Whether operating margin can continue to improve driven by higher capacity utilization.
• Progress in humanoid robot customer nominations, order growth, and FY3/27 revenue reaching ¥4.2bn.
• Whether actuator products can be commercialized as planned within about the next 1.5 years.
• Whether monthly capacity in the United States can increase from 8,000–9,000 units to 10,000–15,000 units by the end of 2026.
• Achievement of the raised FY3/27 targets for sales, operating profit, and net profit.